MEI 
Welcome,         Profile    Billing    Logout  
 6 Products   38 Diseases  6 Products   5 Trials   637 News 
13 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
voruciclib (ME-522) / MEI
NCT03547115: A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML

Checkmark Data from trial for r/r B-cell malignancies or AML at ASH 2021
Nov 2021 - Nov 2021: Data from trial for r/r B-cell malignancies or AML at ASH 2021
Checkmark Initiation of combination trial in B cell malignancies
Jun 2018 - Jun 2018: Initiation of combination trial in B cell malignancies
Recruiting
1
100
US
voruciclib monotherapy, ME-522, voruciclib and venetoclax, VENCLEXTA®
MEI Pharma, Inc.
Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML)
04/24
03/25
ME-344 / MEI
NCT05824559: ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer

Terminated
1
23
US
ME-344, Bevacizumab
MEI Pharma, Inc.
Colorectal Cancer
07/24
07/24
phenoxodiol (NV06) / MEI
ACTRN12618001073291: An early phase clinical trial evaluating the effectiveness of treatment of 177Lu-PSMA with idronoxil in men with castrate-resistant prostate cancer (LuPin Trial)

Completed
1
56
 
St Vincent's Hospital Sydney, Noxopharm Limited
Castrate-resistant prostate cancer
 
 
pracinostat (SB939) / Helsinn, MEI, Menarini
ACTRN12619001655134p: A study investigating different combinations of Cytarabine, Midistaurin, Pracinostat and Venetoclax in elderly patients with Acute Myeloid Leukaemia to extend remission.

Not yet recruiting
2
308
 
The Australasian Leukaemia and Lymphoma Group, Medical Research Future Fund (MRFF)
Acute Myeloid Leukaemia
 
 
ACTRN12619001655134: A study investigating different combinations of Cytarabine, Midistaurin, Pracinostat and Venetoclax in elderly patients with Acute Myeloid Leukaemia to extend remission.

Recruiting
2
208
 
The Australasian Leukaemia and Lymphoma Group, Medical Research Future Fund (MRFF)
Acute Myeloid Leukaemia
 
 
zandelisib (ME-401) / MEI
COASTAL, NCT04745832 / 2020-004199-16: Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL -

Terminated
3
82
Europe, Canada, Japan, US, RoW
Zandelisib, ME-401, Rituximab, Rituxan, MabThera, Bendamustine, Bendeka, Treanda, Belrapzo, CHOP, cyclophosphamide 750 mg/m2, hydroxydoxorubicin IV 50 mg/m2, vincristine IV 1.4 mg/m2 and prednisone 100 mg daily
MEI Pharma, Inc., Kyowa Kirin, Inc.
Follicular Lymphoma (FL), Non Hodgkin Lymphoma, Marginal Zone Lymphoma
03/23
03/23
CORAL, NCT05209308: Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL

Withdrawn
2
42
US
Zandelisib, ME-401, Rituximab, Rituxan, MabThera, Venetoclax, Venclexta
MEI Pharma, Inc., Kyowa Kirin, Inc.
CLL
03/23
03/23
TIDAL, NCT03768505 / 2018-002896-17: Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies

Terminated
2
169
Europe, US, RoW
Zandelisib (ME-401)
MEI Pharma, Inc.
Follicular Lymphoma (FL), Non Hodgkin Lymphoma, Marginal Zone Lymphoma
03/23
03/23
ME-401-K02, NCT04533581: Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)

Active, not recruiting
2
61
Japan
ME-401
Kyowa Kirin Co., Ltd.
Indolent B-cell Non-Hodgkin's Lymphoma
05/28
05/28
NCT04517435: ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma

Terminated
1/2
13
US
ME-401, PWT-143, Rituximab, Rituxan, Mabthera, Cyclophosphamide, Cytoxan, Doxorubicin, Doxorubicin Hydrochloride, Vincristine, OncovinTM, Prednisone
Deepa Jagadeesh, Case Comprehensive Cancer Center
Diffuse Large B-Cell Lymphoma
05/23
05/23
NCT05604417: Zandelisib + Tazemetostat in R/R Follicular Lymphoma

Withdrawn
1/2
34
NA
TAZEMETOSTAT, TAZVERIK, Zandelisib, ME-401
Jacob Soumerai, MD, MEI Pharma, Inc.
Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma
12/24
12/26
ME-401-002, NCT02914938: A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma

Terminated
1
97
Europe, US
ME-401, Rituximab, Rituxan, Zanubrutinib
MEI Pharma, Inc.
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma (FL), Marginal Zone B Cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), High Grade Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma (MCL)
03/23
03/23
NCT03985189: Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma

Active, not recruiting
1
14
Japan
ME-401
Kyowa Kirin Co., Ltd.
Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
05/28
05/28
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
voruciclib (ME-522) / MEI
NCT03547115: A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML

Checkmark Data from trial for r/r B-cell malignancies or AML at ASH 2021
Nov 2021 - Nov 2021: Data from trial for r/r B-cell malignancies or AML at ASH 2021
Checkmark Initiation of combination trial in B cell malignancies
Jun 2018 - Jun 2018: Initiation of combination trial in B cell malignancies
Recruiting
1
100
US
voruciclib monotherapy, ME-522, voruciclib and venetoclax, VENCLEXTA®
MEI Pharma, Inc.
Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML)
04/24
03/25
ME-344 / MEI
NCT05824559: ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer

Terminated
1
23
US
ME-344, Bevacizumab
MEI Pharma, Inc.
Colorectal Cancer
07/24
07/24
phenoxodiol (NV06) / MEI
ACTRN12618001073291: An early phase clinical trial evaluating the effectiveness of treatment of 177Lu-PSMA with idronoxil in men with castrate-resistant prostate cancer (LuPin Trial)

Completed
1
56
 
St Vincent's Hospital Sydney, Noxopharm Limited
Castrate-resistant prostate cancer
 
 
pracinostat (SB939) / Helsinn, MEI, Menarini
ACTRN12619001655134p: A study investigating different combinations of Cytarabine, Midistaurin, Pracinostat and Venetoclax in elderly patients with Acute Myeloid Leukaemia to extend remission.

Not yet recruiting
2
308
 
The Australasian Leukaemia and Lymphoma Group, Medical Research Future Fund (MRFF)
Acute Myeloid Leukaemia
 
 
ACTRN12619001655134: A study investigating different combinations of Cytarabine, Midistaurin, Pracinostat and Venetoclax in elderly patients with Acute Myeloid Leukaemia to extend remission.

Recruiting
2
208
 
The Australasian Leukaemia and Lymphoma Group, Medical Research Future Fund (MRFF)
Acute Myeloid Leukaemia
 
 
zandelisib (ME-401) / MEI
COASTAL, NCT04745832 / 2020-004199-16: Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL -

Terminated
3
82
Europe, Canada, Japan, US, RoW
Zandelisib, ME-401, Rituximab, Rituxan, MabThera, Bendamustine, Bendeka, Treanda, Belrapzo, CHOP, cyclophosphamide 750 mg/m2, hydroxydoxorubicin IV 50 mg/m2, vincristine IV 1.4 mg/m2 and prednisone 100 mg daily
MEI Pharma, Inc., Kyowa Kirin, Inc.
Follicular Lymphoma (FL), Non Hodgkin Lymphoma, Marginal Zone Lymphoma
03/23
03/23
CORAL, NCT05209308: Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL

Withdrawn
2
42
US
Zandelisib, ME-401, Rituximab, Rituxan, MabThera, Venetoclax, Venclexta
MEI Pharma, Inc., Kyowa Kirin, Inc.
CLL
03/23
03/23
TIDAL, NCT03768505 / 2018-002896-17: Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies

Terminated
2
169
Europe, US, RoW
Zandelisib (ME-401)
MEI Pharma, Inc.
Follicular Lymphoma (FL), Non Hodgkin Lymphoma, Marginal Zone Lymphoma
03/23
03/23
ME-401-K02, NCT04533581: Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)

Active, not recruiting
2
61
Japan
ME-401
Kyowa Kirin Co., Ltd.
Indolent B-cell Non-Hodgkin's Lymphoma
05/28
05/28
NCT04517435: ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma

Terminated
1/2
13
US
ME-401, PWT-143, Rituximab, Rituxan, Mabthera, Cyclophosphamide, Cytoxan, Doxorubicin, Doxorubicin Hydrochloride, Vincristine, OncovinTM, Prednisone
Deepa Jagadeesh, Case Comprehensive Cancer Center
Diffuse Large B-Cell Lymphoma
05/23
05/23
NCT05604417: Zandelisib + Tazemetostat in R/R Follicular Lymphoma

Withdrawn
1/2
34
NA
TAZEMETOSTAT, TAZVERIK, Zandelisib, ME-401
Jacob Soumerai, MD, MEI Pharma, Inc.
Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma
12/24
12/26
ME-401-002, NCT02914938: A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma

Terminated
1
97
Europe, US
ME-401, Rituximab, Rituxan, Zanubrutinib
MEI Pharma, Inc.
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma (FL), Marginal Zone B Cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), High Grade Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma (MCL)
03/23
03/23
NCT03985189: Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma

Active, not recruiting
1
14
Japan
ME-401
Kyowa Kirin Co., Ltd.
Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
05/28
05/28

Download Options